{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:23:38Z","timestamp":1761092618013,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.cardfail.2019.05.014","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T20:02:39Z","timestamp":1559332959000},"page":"686-689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeted Mono-Therapy for Newly Diagnosed Dilated Cardiomyopathy"],"prefix":"10.1016","volume":"25","author":[{"given":"Indranee","family":"Rajapreyar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan","family":"Samson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre Vladimir","family":"Ennezat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry H Le","family":"Jemtel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2019.05.014_bib0001","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0002","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"Group","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0003","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0004","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"Yusuf","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0005","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(03)13501-5","article-title":"Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study","volume":"361","author":"Jong","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0006","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cardfail.2016.03.017","article-title":"Pharmacologic and endovascular reversal of left ventricular remodeling","volume":"22","author":"Jaiswal","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0007","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0008","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0009","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0010","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0011","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1152\/japplphysiol.00832.2009","article-title":"The 2009 Carl Ludwig Lecture: Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management","volume":"108","author":"Esler","year":"2010","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0012","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1161\/CIRCRESAHA.111.245092","article-title":"Treatment of chronic heart failure with beta-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology","volume":"109","author":"Bristow","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0013","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1161\/01.CIR.80.3.551","article-title":"Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol","volume":"80","author":"Waagstein","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0014","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1161\/CIRCOUTCOMES.111.000045","article-title":"Natural history of left ventricular ejection fraction in patients with heart failure","volume":"6","author":"Clarke","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0015","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/CIRCHEARTFAILURE.113.000813","article-title":"Long-term functional and clinical follow-up of patients with heart failure with recovered left ventricular ejection fraction after beta-blocker therapy","volume":"7","author":"de Groote","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0016","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/CIRCULATIONAHA.106.666016","article-title":"Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial","volume":"116","author":"Colucci","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0017","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0018","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","volume":"23","author":"Yancy","year":"2017","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0019","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","article-title":"Combined angiotensin receptor antagonism and neprilysin inhibition","volume":"133","author":"Hubers","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0020","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0021","doi-asserted-by":"crossref","first-page":"e12435","DOI":"10.1111\/1755-5922.12435","article-title":"The reverse remodeling response to sacubitril\/valsartan therapy in heart failure with reduced ejection fraction","volume":"36","author":"Martens","year":"2018","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0022","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.jacc.2004.05.087","article-title":"Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure","volume":"44","author":"Sliwa","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0023","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1023\/B:CARD.0000025756.32499.6f","article-title":"The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN)","volume":"18","author":"Remme","year":"2004","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0024","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.105.582320","article-title":"Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III","volume":"112","author":"Willenheimer","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ahj.2007.08.010","article-title":"Recovery of normal ventricular function in patients with dilated cardiomyopathy: predictors of an increasingly prevalent clinical event","volume":"155","author":"Binkley","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0026","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1388-9842(00)00150-1","article-title":"Frequency, prognosis and predictors of improvement of systolic left ventricular function in patients with \u201cclassical\u201d clinical diagnosis of idiopathic dilated cardiomyopathy","volume":"3","author":"Cicoira","year":"2001","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0027","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cardfail.2003.10.002","article-title":"Chronic left ventricular failure in the community: prevalence, prognosis, and predictors of the complete clinical recovery with return of cardiac size and function to normal in patients undergoing optimal therapy","volume":"10","author":"Cioffi","year":"2004","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0028","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0735-1097(03)00262-6","article-title":"Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials","volume":"41","author":"Shekelle","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0029","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1161\/01.CIR.103.3.375","article-title":"Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II)","volume":"103","author":"Simon","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0030","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1161\/CIRCULATIONAHA.105.586545","article-title":"Angiotensin-converting enzyme inhibitors or beta-blockers in heart failure: does it matter who goes first?","volume":"112","author":"Fang","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0031","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/eurjhf\/hfr051","article-title":"Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial","volume":"13","author":"Funck-Brentano","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0032","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","article-title":"Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF","volume":"38","author":"Bohm","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2019.05.014_bib0033","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators","volume":"94","author":"Bristow","year":"1996","journal-title":"Circulation"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916419303781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916419303781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:42:40Z","timestamp":1761028960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916419303781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1071916419303781"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2019.05.014","relation":{},"ISSN":["1071-9164"],"issn-type":[{"type":"print","value":"1071-9164"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Mono-Therapy for Newly Diagnosed Dilated Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2019.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}